Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting

Syed Sameer Nasir, Lee Schwartzberg

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of cancer therapy. The goal of CINV prophylaxis is to reduce the morbidity associated with nausea and vomiting, as well as to preserve quality of life, while maintaining the desired chemotherapy regimen. The US Food and Drug Administration has recently approved new therapies for prevention of CINV, including the neurokinin-1 (NK1) receptor antagonist rolapitant and the fixed-dose combination of the second-generation 5-hydroxytryptamine type 3 receptor antagonist palonosetron with the novel NK1 receptor antagonist netupitant. Alternative agents, like the atypical antipsychotic olanzapine, have also expanded the options available for preventing delayed and refractory CINV. Consensus guidelines for prevention of CINV from several organizations are generally consistent with one another and are updated based on expert review of available clinical trial data. This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.

Original languageEnglish (US)
Pages (from-to)750-762
Number of pages13
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number8
StatePublished - Aug 1 2016

Fingerprint

Nausea
Vomiting
Drug Therapy
Neurokinin-1 Receptor Antagonists
Guidelines
olanzapine
Receptors, Serotonin, 5-HT3
Physician's Role
Antiemetics
United States Food and Drug Administration
Antipsychotic Agents
Consensus
Quality of Life
Clinical Trials
Organizations
Morbidity
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting. / Nasir, Syed Sameer; Schwartzberg, Lee.

In: Oncology (Williston Park, N.Y.), Vol. 30, No. 8, 01.08.2016, p. 750-762.

Research output: Contribution to journalReview article

@article{942d17e41aa542f3bc426c07e483cea9,
title = "Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting",
abstract = "Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of cancer therapy. The goal of CINV prophylaxis is to reduce the morbidity associated with nausea and vomiting, as well as to preserve quality of life, while maintaining the desired chemotherapy regimen. The US Food and Drug Administration has recently approved new therapies for prevention of CINV, including the neurokinin-1 (NK1) receptor antagonist rolapitant and the fixed-dose combination of the second-generation 5-hydroxytryptamine type 3 receptor antagonist palonosetron with the novel NK1 receptor antagonist netupitant. Alternative agents, like the atypical antipsychotic olanzapine, have also expanded the options available for preventing delayed and refractory CINV. Consensus guidelines for prevention of CINV from several organizations are generally consistent with one another and are updated based on expert review of available clinical trial data. This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.",
author = "Nasir, {Syed Sameer} and Lee Schwartzberg",
year = "2016",
month = "8",
day = "1",
language = "English (US)",
volume = "30",
pages = "750--762",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - Recent Advances in Preventing Chemotherapy-Induced Nausea and Vomiting

AU - Nasir, Syed Sameer

AU - Schwartzberg, Lee

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of cancer therapy. The goal of CINV prophylaxis is to reduce the morbidity associated with nausea and vomiting, as well as to preserve quality of life, while maintaining the desired chemotherapy regimen. The US Food and Drug Administration has recently approved new therapies for prevention of CINV, including the neurokinin-1 (NK1) receptor antagonist rolapitant and the fixed-dose combination of the second-generation 5-hydroxytryptamine type 3 receptor antagonist palonosetron with the novel NK1 receptor antagonist netupitant. Alternative agents, like the atypical antipsychotic olanzapine, have also expanded the options available for preventing delayed and refractory CINV. Consensus guidelines for prevention of CINV from several organizations are generally consistent with one another and are updated based on expert review of available clinical trial data. This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.

AB - Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of cancer therapy. The goal of CINV prophylaxis is to reduce the morbidity associated with nausea and vomiting, as well as to preserve quality of life, while maintaining the desired chemotherapy regimen. The US Food and Drug Administration has recently approved new therapies for prevention of CINV, including the neurokinin-1 (NK1) receptor antagonist rolapitant and the fixed-dose combination of the second-generation 5-hydroxytryptamine type 3 receptor antagonist palonosetron with the novel NK1 receptor antagonist netupitant. Alternative agents, like the atypical antipsychotic olanzapine, have also expanded the options available for preventing delayed and refractory CINV. Consensus guidelines for prevention of CINV from several organizations are generally consistent with one another and are updated based on expert review of available clinical trial data. This article will address changes in CINV guidelines over the past 5 years and provide updates on recently approved agents and agents that are expected to be approved, based on published phase III trials. It will also explore other factors affecting optimal CINV control, including the role of patient-related risk factors and the role of physician adherence to antiemetic guidelines in reducing the residual risk of CINV.

UR - http://www.scopus.com/inward/record.url?scp=85049231994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049231994&partnerID=8YFLogxK

M3 - Review article

VL - 30

SP - 750

EP - 762

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8

ER -